TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1921523

Group type: EXPERIMENTAL
Intervention: Group 1 (usual care + reminder call)
Number of subjects: 2201

Group type: EXPERIMENTAL
Intervention: Group 2 (usual care + self‐held screening booklet + reminder call)
Number of subjects: 2201

Group type: EXPERIMENTAL
Intervention: Group 3 (usual care + self‐held screening booklet + instruction call + reminder call)
Number of subjects: 2201

Group type: COMPARATOR
Intervention: Control Group (advance letter, screening kit, reminder letter)
Number of subjects: 2201
Study: 3899666

Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM) 20 mg/day for 1 yr
Number of subjects: 1005

Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM)
Number of subjects: 1005

Group type: COMPARATOR
Intervention: Control (no further treatment)
Number of subjects: 1005

Group type: COMPARATOR
Intervention: Ovarian irradiation
Number of subjects: 1005
Study: 30887776

Group type: EXPERIMENTAL
Intervention: New method for de-noising ICG signal based on adaptive ensemble empirical mode decomposition and wavelet threshold
Number of subjects: 30
Study: 30400372

Group type: EXPERIMENTAL
Intervention: Ancient wheat foodstuffs (made of organic KAMUT® khorasan wheat)
Number of subjects: 63
Study: 26524933

Group type: EXPERIMENTAL
Intervention: Epinephrine (0.33 mg/L) added to saline irrigation fluid
Number of subjects: 101

Group type: COMPARATOR
Intervention: Regular saline irrigation fluid (control group)
Number of subjects: 101
Study: 25257804

Group type: EXPERIMENTAL
Intervention: Early specialized palliative care (SPC)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 300
Study: 22295814

Group type: EXPERIMENTAL
Intervention: Warming‐promotion acupuncture
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal acupuncture
Number of subjects: 60
Study: 20205481

Group type: EXPERIMENTAL
Intervention: Oral rehydration therapy (ORT)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Subcutaneous rehydration therapy (SCRT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intravenous rehydration therapy (IVRT)
Number of subjects: 20
Study: 21575243

Group type: EXPERIMENTAL
Intervention: Water aerobics (3 classes per week)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Routine antenatal care
Number of subjects: 66
Study: 16022023

Group type: EXPERIMENTAL
Intervention: Adjunctive local delivery of extracts from Centella asiatica and Punica granatum
Number of subjects: 15

Group type: COMPARATOR
Intervention: Standard supportive periodontal therapy (SPT)
Number of subjects: 15
Study: 12446187

Group type: EXPERIMENTAL
Intervention: Cheese containing Lactobacillus rhamnosus GG and Lactobacillus rhamnosus LC 705, 5 x 15 g per day for 3 weeks
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Both intervention and control groups
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Probiotic intervention
Number of subjects: 74
Study: 9667705

Group type: EXPERIMENTAL
Intervention: Woven grafts
Number of subjects: 267

Group type: COMPARATOR
Intervention: Knitted collagen-impregnated Dacron grafts
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Both graft types
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Knitted grafts
Number of subjects: 267
Study: 8076229

Group type: EXPERIMENTAL
Intervention: Midazolam (0.07 mg.kg‐1 for <65 years, 0.06 mg.kg‐1 for ≥65 years)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Diazepam (0.15 mg.kg‐1 for <65 years, 0.11 mg.kg‐1 for ≥65 years)
Number of subjects: 100
Study: 2531570

Group type: EXPERIMENTAL
Intervention: Calcipotriol 25 micrograms/g
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Calcipotriol 50 micrograms/g
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Calcipotriol 100 micrograms/g
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (vehicle alone)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Overall treatment with calcipotriol ointment
Number of subjects: 50
Study: 30325703

Group type: EXPERIMENTAL
Intervention: SAC program (high stress shooting with real persons)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Dummy men training (low stress)
Number of subjects: 98
Study: 28846532

Group type: EXPERIMENTAL
Intervention: Rigid fixation using sternal plates (Group R)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Sternal wire fixation (Group C)
Number of subjects: 80
Study: 26324362

Group type: EXPERIMENTAL
Intervention: XELOX (oxaliplatin 130 mg/m² on day 1 and capecitabine 1,000 mg/m² twice daily on days 1 to 14 every 3 weeks for 6 months)
Number of subjects: 1886

Group type: COMPARATOR
Intervention: FU/FA (bolus fluorouracil/folinic acid for 6 months)
Number of subjects: 1886

Group type: EXPERIMENTAL
Intervention: XELOX
Number of subjects: 1886

Group type: COMPARATOR
Intervention: FU/FA
Number of subjects: 1886
Study: 23799929

Group type: EXPERIMENTAL
Intervention: Subcutaneous nerve stimulation (SQS) plus optimized medical management
Number of subjects: 400

Group type: COMPARATOR
Intervention: Optimized medical management (OMM) alone
Number of subjects: 400
Study: 20466200

Group type: EXPERIMENTAL
Intervention: High-dose N-acetylcysteine (2 x 1,200 mg/day for 48 h)
Number of subjects: 251

Group type: COMPARATOR
Intervention: Placebo plus optimal hydration
Number of subjects: 251
Study: 18419497

Group type: EXPERIMENTAL
Intervention: Planned treatment interruption with nevirapine
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Planned treatment interruption with efavirenz
Number of subjects: 35

Group type: COMPARATOR
Intervention: Continuous therapy (control group)
Number of subjects: 35
Study: 17206976

Group type: EXPERIMENTAL
Intervention: Early administration of atosiban
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard administration of atosiban
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early atosiban administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard atosiban administration
Number of subjects: 0
Study: 12545081

Group type: EXPERIMENTAL
Intervention: RTV/IDV (100/400 mg bid)
Number of subjects: 20

Group type: COMPARATOR
Intervention: IDV (800 mg tid)
Number of subjects: 20
Study: 10767070

Group type: EXPERIMENTAL
Intervention: Prospective navigator-echo respiratory gating (NE)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Breath-hold imaging (BH)
Number of subjects: 24
Study: 8781321

Group type: EXPERIMENTAL
Intervention: 520-kcal diet with less than 2 g fat/d
Number of subjects: 13

Group type: COMPARATOR
Intervention: 900-kcal diet with 30 g fat/d (including one 10-g fat meal)
Number of subjects: 13
Study: 1596317

Group type: EXPERIMENTAL
Intervention: 250 mg Methylprednisolone
Number of subjects: 51

Group type: COMPARATOR
Intervention: 10 ml NaCl 0.9%
Number of subjects: 51
Study: 3156544

Group type: EXPERIMENTAL
Intervention: Atracurium 0.6mg/kg
Number of subjects: 51

Group type: COMPARATOR
Intervention: Alcuronium 0.25mg/kg
Number of subjects: 51
Study: 29468670

Group type: EXPERIMENTAL
Intervention: Community-based rapid rehousing
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Permanent subsidy
Number of subjects: 172

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 172
Study: 29352007

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 14793

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 14793
Study: 27501833

Group type: EXPERIMENTAL
Intervention: D6 (heel-to-toe drop of 6 mm)
Number of subjects: 553

Group type: EXPERIMENTAL
Intervention: D0 (heel-to-toe drop of 0 mm)
Number of subjects: 553

Group type: EXPERIMENTAL
Intervention: D6 and D0 (low-drop shoes) in occasional runners
Number of subjects: 553
Study: 25275230

Group type: EXPERIMENTAL
Intervention: Continuous jejunal infusion of levodopa-carbidopa intestinal gel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard oral levodopa therapy
Number of subjects: 0
Study: 23207562

Group type: COMPARATOR
Intervention: Normal saline wrapping (Group I, N=10)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: NG solution wrapping (Group II, N=11)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: 2 cc NG injection (Group III, N=10)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Normal saline injection (Group IV, N=10)
Number of subjects: 41
Study: 20485146

Group type: EXPERIMENTAL
Intervention: Laparoscopically assisted colorectal resection
Number of subjects: 52

Group type: COMPARATOR
Intervention: Open colorectal resection
Number of subjects: 52
Study: 18588611

Group type: EXPERIMENTAL
Intervention: Oxytocin alone
Number of subjects: 150

Group type: COMPARATOR
Intervention: Propranolol plus oxytocin
Number of subjects: 150
Study: 15752663

Group type: EXPERIMENTAL
Intervention: Chlormadinone acetate (10 mg once a day from day 5 to day 25)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Chlormadinone acetate (10 mg once a day from day 8 to day 25)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Chlormadinone acetate (both groups)
Number of subjects: 20
Study: 12228784

Group type: EXPERIMENTAL
Intervention: Enoxaparin plus ASA
Number of subjects: 525

Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH) plus ASA
Number of subjects: 525
Study: 9477058

Group type: EXPERIMENTAL
Intervention: Partial neuromuscular block with vecuronium (mean TOF ratio 50%)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Breathing through a resistor
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Breathing 5% carbon dioxide
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Breathing with inspiratory resistor
Number of subjects: 6
Study: 7605013

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control (no specific control intervention mentioned)
Number of subjects: 21
Study: 1978689

Group type: EXPERIMENTAL
Intervention: Tryptophan (TRP), up to 6 g/day, administered for 25-35 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 686893

Group type: EXPERIMENTAL
Intervention: Prophylactic oral neomycin and erythromycin base
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31673828

Group type: EXPERIMENTAL
Intervention: Chronic peritoneal dialysis with concurrent colostomy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (children on chronic peritoneal dialysis without colostomy)
Number of subjects: 20
Study: 31070699

Group type: EXPERIMENTAL
Intervention: Teleretinal screening (TR)
Number of subjects: 801

Group type: COMPARATOR
Intervention: Universal referral (UR)
Number of subjects: 801
Study: 25603481

Group type: EXPERIMENTAL
Intervention: Irrigation pressure at 150 cm (Group 3)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Irrigation pressure at 100 cm (Group 2)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Irrigation pressure at 80 cm (Group 1)
Number of subjects: 168
Study: 24938534

Group type: EXPERIMENTAL
Intervention: Selenium-enriched yeast (SY) 200 or 285 μg/day
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Selenium-enriched yeast (SY) high-dose
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Selenium-enriched yeast (SY) low-dose
Number of subjects: 69

Group type: COMPARATOR
Intervention: Selenomethionine (SeMet) 200 μg/day
Number of subjects: 69
Study: 22775364

Group type: EXPERIMENTAL
Intervention: Life review intervention
Number of subjects: 202

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 202
Study: 19106728

Group type: EXPERIMENTAL
Intervention: Pharmacist contact with the patient via telephone
Number of subjects: 3048

Group type: EXPERIMENTAL
Intervention: Pharmacist contact with the patient's prescribing physician via facsimile
Number of subjects: 3048

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 3048
Study: 17895968

Group type: COMPARATOR
Intervention: CytoMax (C)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Leading sports drink (G)
Number of subjects: 6
Study: 15077100

Group type: EXPERIMENTAL
Intervention: Eptifibatide
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 12356654

Group type: EXPERIMENTAL
Intervention: Lithium augmentation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 50
Study: 9272335

Group type: EXPERIMENTAL
Intervention: DTaP vaccine
Number of subjects: 10271

Group type: COMPARATOR
Intervention: DTP vaccine
Number of subjects: 10271

Group type: COMPARATOR
Intervention: DT vaccine
Number of subjects: 10271
Study: 8220939

Group type: EXPERIMENTAL
Intervention: misoprostol 400-800 micrograms daily
Number of subjects: 301

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 301
Study: 3806169

Group type: EXPERIMENTAL
Intervention: Adjuvant methotrexate (MTX) started at 40 mg/m2 and escalated by 10 mg/m2 weekly, with four doses preoperatively, four doses postoperatively before radiation therapy, and eight doses post-radiation therapy.
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (no adjuvant MTX)
Number of subjects: 55
Study: 31138085

Group type: EXPERIMENTAL
Intervention: NfL levels (measured using Single Molecule Array technology)
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: NfL levels incorporated into predictive score
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Independent predictors of serum NfL
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Cardiovascular disease risk factors
Number of subjects: 363
Study: 29318342

Group type: EXPERIMENTAL
Intervention: Usual care plus group‐CBT (17 group sessions)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 158
Study: 26645932

Group type: EXPERIMENTAL
Intervention: Cloud-based diabetes management program
Number of subjects: 40
Study: 24191893

Group type: EXPERIMENTAL
Intervention: 750 mg/day probucol plus 160 mg/day valsartan
Number of subjects: 69

Group type: COMPARATOR
Intervention: 160 mg/day valsartan
Number of subjects: 69
Study: 22812414

Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 202

Group type: COMPARATOR
Intervention: Control (CsA)
Number of subjects: 202
Study: 20601912

Group type: EXPERIMENTAL
Intervention: Silicone hydrogel lenses with multipurpose solutions
Number of subjects: 0
Study: 17664467

Group type: EXPERIMENTAL
Intervention: Docetaxel plus cisplatin and fluorouracil (DCF)
Number of subjects: 445

Group type: COMPARATOR
Intervention: Cisplatin and fluorouracil (CF)
Number of subjects: 445
Study: 16287499

Group type: EXPERIMENTAL
Intervention: Red wine (RW)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dealcoholized red wine (DRW)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Water
Number of subjects: 0
Study: 12946081

Group type: EXPERIMENTAL
Intervention: Manual‐assisted cognitive behaviour therapy (MACT)
Number of subjects: 480

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: MACT
Number of subjects: 480
Study: 11916603

Group type: EXPERIMENTAL
Intervention: Early atropine administration
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional atropine administration
Number of subjects: 120
Study: 9160597

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Anxiety Sensitivity Index (ASI)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 106
Study: 1303775

Group type: EXPERIMENTAL
Intervention: Cetirizine (Zyrtec 10 mg/day)
Number of subjects: 14
Study: 2864486

Group type: EXPERIMENTAL
Intervention: 50 mg zinc per day as zinc acetate
Number of subjects: 32

Group type: COMPARATOR
Intervention: No zinc supplementation (control group)
Number of subjects: 32
Study: 3623260

Group type: EXPERIMENTAL
Intervention: Calcium (375 mg/day) and vitamin D (1,200 IU/day) supplementation
Number of subjects: 200

Group type: COMPARATOR
Intervention: Non-supplemented group
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Calcium and vitamin D supplementation
Number of subjects: 200
Study: 31473464

Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy (MET)
Number of subjects: 56
Study: 28987529

Group type: EXPERIMENTAL
Intervention: Standardized percutaneous needle electrolysis (PNE) protocol for AWS
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard physiotherapy intervention for AWS
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups (PNE and physiotherapy)
Number of subjects: 100
Study: 25327635

Group type: EXPERIMENTAL
Intervention: Hyperemesis gravidarum (HG) patients
Number of subjects: 80

Group type: COMPARATOR
Intervention: Healthy pregnant women (control)
Number of subjects: 80
Study: 23151774

Group type: EXPERIMENTAL
Intervention: Agomelatine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21519085

Group type: EXPERIMENTAL
Intervention: Specific preoperative information on the procedure and written instructions on postoperative care (n=28)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Standard preoperative information and verbal instructions on postoperative care (n=27)
Number of subjects: 55
Study: 19236727

Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg (Eso20)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Pectin‐based raft‐forming agent (PRA)
Number of subjects: 77
Study: 16434738

Group type: EXPERIMENTAL
Intervention: Xylitol 6.88 g/day (G3)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Xylitol 10.32 g/day (G4)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control (sorbitol/maltitol) (G1)
Number of subjects: 132
Study: 15333426

Group type: EXPERIMENTAL
Intervention: Closed suctioning (CS) system (TrachCare)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Open suctioning (OS) system
Number of subjects: 24
Study: 10679534

Group type: EXPERIMENTAL
Intervention: Active intervention (asthma education and optimisation of drug therapy)
Number of subjects: 689

Group type: COMPARATOR
Intervention: Control group (no active intervention)
Number of subjects: 689
Study: 9333148

Group type: EXPERIMENTAL
Intervention: Immunization with recombinant HIV-1 gp160
Number of subjects: 0

Group type: COMPARATOR
Intervention: Zidovudine alone or in combination with the immunogen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immunization with gp160
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antiretroviral therapy
Number of subjects: 0
Study: 8222665

Group type: EXPERIMENTAL
Intervention: 1 g ascorbic acid taken 1/2 hour before OC intake
Number of subjects: 37

Group type: COMPARATOR
Intervention: Combination monophasic oral contraceptive without ascorbic acid
Number of subjects: 37
Study: 2429800

Group type: EXPERIMENTAL
Intervention: Cimetidine, 4 mg/kg, plus placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Chlorpheniramine, 0.1 mg/kg, plus placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cimetidine plus chlorpheniramine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 31616979

Group type: EXPERIMENTAL
Intervention: Advanced Reconstruction of Vesicourethral Support (ARVUS) technique
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nerve-sparing approach (not specified if unilateral or bilateral)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Time after surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nerve-sparing status
Number of subjects: 0
Study: 29727369

Group type: EXPERIMENTAL
Intervention: High-illuminance blue light therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard care plus high-illuminance blue light
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bright blue light
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bright red or ambient white fluorescent light
Number of subjects: 0
Study: 27480676

Group type: EXPERIMENTAL
Intervention: Parental monitoring (self-reported by adolescents)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Parental monitoring (parent-reported)
Number of subjects: 87
Study: 25270585

Group type: EXPERIMENTAL
Intervention: TENS
Number of subjects: 317

Group type: COMPARATOR
Intervention: Placebo-TENS
Number of subjects: 317

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 317
Study: 22689870

Group type: EXPERIMENTAL
Intervention: Mentoring and skills group intervention
Number of subjects: 110
Study: 20214175

Group type: EXPERIMENTAL
Intervention: Clindamycin phosphate 1%/benzoyl peroxide 5% gel (BPO/C)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clindamycin phosphate 1.2%/tretinoin 0.025% gel (T/C)
Number of subjects: 0
Study: 18023130

Group type: EXPERIMENTAL
Intervention: TTM-based motivational counselling by trained practice nurses
Number of subjects: 1378

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1378
Study: 15953490

Group type: EXPERIMENTAL
Intervention: Reboxetine
Number of subjects: 421

Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 421
Study: 31930830

Group type: EXPERIMENTAL
Intervention: 2,4-D (0, 1, 2) ppm with BAP (0, 0.5, 1) ppm in light and dark conditions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no 2,4-D and BAP)
Number of subjects: 0
Study: 10626316

Group type: EXPERIMENTAL
Intervention: Risk factor-based cognitive behavioral therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Electromyographic biofeedback intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-risk patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Refusers of therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-risk patients
Number of subjects: 0
Study: 7738941

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 496

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 496
Study: 2076342

Group type: EXPERIMENTAL
Intervention: Transdermal therapeutic system of scopolamine (TTS-S)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Transdermal placebo (TD-P)
Number of subjects: 130
Study: 7288807

Group type: EXPERIMENTAL
Intervention: (+)-isomer of tranylcypromine at doses below 3 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: (-)-isomer of tranylcypromine
Number of subjects: 0
Study: 30125510

Group type: EXPERIMENTAL
Intervention: Kaplan-Meier progression-free survival data from the CLEOPATRA trial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Kaplan-Meier overall survival data from the CLEOPATRA trial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Parametric functions fitted to survival data
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interim analyses of clinical trial data
Number of subjects: 0
Study: 26475680

Group type: EXPERIMENTAL
Intervention: Lifestyle physical activity program
Number of subjects: 0